Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q

Epidermal growth factor receptor (EGFR) L718Q is a rare resistant mutation which independently leads to third-generation tyrosine kinase inhibitor (TKI) resistance. Although a few studies have examined its resistance mechanisms, no effective treatment strategy has yet been proposed for patients with...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Thorac Dis
Glavni autori: Song, Yang, Jia, Ziqi, Wang, Yadong, Wang, Yanyu, Liu, Peng, Zhang, Shuyang, Bing, Zhongxing, Cao, Lei, Cao, Zhili, Rossi, Elisabetta, Zamarchi, Rita, Denis, Marc G., Camps, Carlos, Fernandez-Diaz, Amaya B., Liang, Naixin, Li, Shanqing
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2020
Teme:
iMDT Corner
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7330377/
https://ncbi.nlm.nih.gov/pubmed/32642185
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2020.03.29
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items